Mirum Pharmaceuticals Stock Buy Hold or Sell Recommendation
| MIRM Stock | USD 48.44 0.16 0.33% |
Given the investment horizon of 90 days and your way above-average risk tolerance, our recommendation regarding Mirum Pharmaceuticals is 'Hold'. The recommendation algorithm takes into account all of Mirum Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site.
Check out Mirum Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide. Note, we conduct extensive research on individual companies such as Mirum and provide practical buy, sell, or hold advice based on investors' constraints. Mirum Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Mirum |
Execute Mirum Pharmaceuticals Buy or Sell Advice
The Mirum recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Mirum Pharmaceuticals. Macroaxis does not own or have any residual interests in Mirum Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Mirum Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | OK | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Mirum Pharmaceuticals Trading Alerts and Improvement Suggestions
| The company reported the previous year's revenue of 186.37 M. Net Loss for the year was (163.41 M) with profit before overhead, payroll, taxes, and interest of 223.14 M. | |
| Mirum Pharmaceuticals currently holds about 124.95 M in cash with (70.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.82. | |
| Mirum Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Mirum Pharmaceuticals stock soars to all-time high of 48.94 - MSN |
Mirum Pharmaceuticals Returns Distribution Density
The distribution of Mirum Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Mirum Pharmaceuticals' future price movements. The chart of the probability distribution of Mirum Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Mirum Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Mirum Pharmaceuticals returns is essential to provide solid investment advice for Mirum Pharmaceuticals.
| Mean Return | 0.35 | Value At Risk | -3.05 | Potential Upside | 5.04 | Standard Deviation | 2.48 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Mirum Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Mirum Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Mirum Pharmaceuticals, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Mirum Pharmaceuticals back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 936.2 K | Pictet Asset Manangement Sa | 2024-09-30 | 895.7 K | Clearbridge Advisors, Llc | 2024-09-30 | 889.1 K | Lord, Abbett & Co Llc | 2024-09-30 | 741.4 K | Avidity Partners Management Lp | 2024-09-30 | 731.1 K | Polar Capital Holdings Plc | 2024-09-30 | 675 K | First Turn Management Llc | 2024-09-30 | 647.6 K | Goldman Sachs Group Inc | 2024-09-30 | 638 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 625.9 K | Hhg Plc | 2024-09-30 | 4.5 M | Eventide Asset Management, Llc | 2024-09-30 | 3.4 M |
Mirum Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Mirum Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Mirum Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Mirum stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.33 | |
β | Beta against Dow Jones | 0.05 | |
σ | Overall volatility | 2.47 | |
Ir | Information ratio | 0.11 |
Mirum Pharmaceuticals Volatility Alert
Mirum Pharmaceuticals currently demonstrates below-average downside deviation. It has Information Ratio of 0.11 and Jensen Alpha of 0.33. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Mirum Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Mirum Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Mirum Pharmaceuticals Fundamentals Vs Peers
Comparing Mirum Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Mirum Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Mirum Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Mirum Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Mirum Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Mirum Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Mirum Pharmaceuticals to competition |
| Fundamentals | Mirum Pharmaceuticals | Peer Average |
| Return On Equity | -0.4 | -0.31 |
| Return On Asset | -0.091 | -0.14 |
| Profit Margin | (0.33) % | (1.27) % |
| Operating Margin | (0.14) % | (5.51) % |
| Current Valuation | 2.38 B | 16.62 B |
| Shares Outstanding | 48 M | 571.82 M |
| Shares Owned By Insiders | 2.24 % | 10.09 % |
| Shares Owned By Institutions | 97.76 % | 39.21 % |
| Number Of Shares Shorted | 6.65 M | 4.71 M |
| Price To Earning | (5.20) X | 28.72 X |
| Price To Book | 10.11 X | 9.51 X |
| Price To Sales | 7.64 X | 11.42 X |
| Revenue | 186.37 M | 9.43 B |
| Gross Profit | 223.14 M | 27.38 B |
| EBITDA | (136.49 M) | 3.9 B |
| Net Income | (163.41 M) | 570.98 M |
| Cash And Equivalents | 124.95 M | 2.7 B |
| Cash Per Share | 3.82 X | 5.01 X |
| Total Debt | 308.14 M | 5.32 B |
| Debt To Equity | 0.02 % | 48.70 % |
| Current Ratio | 3.26 X | 2.16 X |
| Book Value Per Share | 4.84 X | 1.93 K |
| Cash Flow From Operations | (70.94 M) | 971.22 M |
| Short Ratio | 15.35 X | 4.00 X |
| Earnings Per Share | (2.08) X | 3.12 X |
| Target Price | 62.7 | |
| Number Of Employees | 311 | 18.84 K |
| Beta | 1.16 | -0.15 |
| Market Capitalization | 2.35 B | 19.03 B |
| Total Asset | 646.62 M | 29.47 B |
| Retained Earnings | (556.24 M) | 9.33 B |
| Working Capital | 300.48 M | 1.48 B |
| Current Asset | 106.8 M | 9.34 B |
Note: Disposition of 6837 shares by Christopher Peetz of Mirum Pharmaceuticals at 47.9243 subject to Rule 16b-3 [view details]
Mirum Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Mirum . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Mirum Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Mirum Pharmaceuticals? Buying financial instruments such as Mirum Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Mirum Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Housewares Thematic Idea Now
Housewares
Companies making housewares accessories and providing houseware services. The Housewares theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Housewares Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Mirum Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirum Pharmaceuticals. If investors know Mirum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirum Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share | Quarterly Revenue Growth 0.894 | Return On Assets | Return On Equity |
The market value of Mirum Pharmaceuticals is measured differently than its book value, which is the value of Mirum that is recorded on the company's balance sheet. Investors also form their own opinion of Mirum Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Mirum Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirum Pharmaceuticals' market value can be influenced by many factors that don't directly affect Mirum Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mirum Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mirum Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirum Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.